|Title||Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.|
|Publication Type||Journal Article|
|Year of Publication||2002|
|Authors||DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM|
|Date Published||2002 Mar 22|
|Keywords||Alzheimer Disease, Amino Acid Substitution, Amyloid beta-Peptides, Amyloidosis, Animals, Antibodies, Monoclonal, Brain, Cerebral Cortex, Disease Models, Animal, Hippocampus, Humans, Mice, Protein Transport, Solubility, Time Factors|
The deposition of amyloid-beta (Abeta) peptides into amyloid plaques precedes the cognitive dysfunction of Alzheimer's disease (AD) by years. Biomarkers indicative of brain amyloid burden could be useful for identifying individuals at high risk for developing AD. As in AD in humans, baseline plasma Abeta levels in a transgenic mouse model of AD did not correlate with brain amyloid burden. However, after peripheral administration of a monoclonal antibody to Abeta (m266), we observed a rapid increase in plasma Abeta and the magnitude of this increase was highly correlated with amyloid burden in the hippocampus and cortex. This method may be useful for quantifying brain amyloid burden in patients at risk for or those who have been diagnosed with AD.
|Grant List||AG20222 / AG / NIA NIH HHS / United States|